Open Orphan Plc (GB:HVO)
LSE:HVO
Top Page
Open Orphan Plc
(LSE:HVO)
Select Model
Select Model
Rating:73Outperform
Price Target:
7.00 p
▼(-1.41% Downside)
Action:ReiteratedDate:12/19/25
Open Orphan Plc's overall stock score is driven by strong financial performance and attractive valuation. The company's robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.
Positive Factors
Proprietary human challenge platform
The proprietary human challenge study platform shortens trial timelines and creates a specialized service offering. That operational IP increases barriers to entry, supports repeat client engagements and strategic partnerships, and drives durable demand from pharma/biotech customers.
Negative Factors
Revenue decline
Fundamentals show material revenue contraction (~-20%), suggesting contract timing issues, client churn or lower demand. Sustained top-line weakness undermines the business's ability to scale fixed costs, fund growth initiatives, and maintain the high-margin profile over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary human challenge platform
The proprietary human challenge study platform shortens trial timelines and creates a specialized service offering. That operational IP increases barriers to entry, supports repeat client engagements and strategic partnerships, and drives durable demand from pharma/biotech customers.
Read all positive factors
Open Orphan Plc (HVO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£48.53M
Dividend Yield2.94%
Average Volume (3M)7.17M
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth11.92%
EPS Growth-33.76%
CountryUK
Employees301
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding688,401,060
10 Day Avg. Volume16,921,125
30 Day Avg. Volume7,174,585
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)2.22
P/FCF Ratio17.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£17.50Price Target Upside146.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£50.48M
Open Orphan Plc Business Overview & Revenue Model
Company Description
Open Orphan Plc (HVO) is a specialist contract research organization (CRO) based in the United Kingdom that focuses on providing services to the pharmaceutical and biotechnology industries. The company specializes in conducting clinical trials for...
How the Company Makes Money
Open Orphan generates revenue primarily through its contract research services, which include conducting clinical trials for clients in the pharmaceutical and biotechnology sectors. The company earns money by charging fees for its clinical trial s...
Open Orphan Plc Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.98M | 62.73M | 56.04M | 48.48M | 36.86M | 20.60M |
| Gross Profit | 57.01M | 62.73M | 10.41M | 4.00M | 35.90M | 19.88M |
| EBITDA | 12.09M | 17.80M | 14.02M | 2.70M | 3.07M | -8.55M |
| Net Income | 5.28M | 10.65M | 16.11M | -776.00K | -74.00K | -10.79M |
Balance Sheet | ||||||
| Total Assets | 85.67M | 88.89M | 83.23M | 51.38M | 42.27M | 48.55M |
| Cash, Cash Equivalents and Short-Term Investments | 23.29M | 44.18M | 36.97M | 28.44M | 15.69M | 19.20M |
| Total Debt | 14.70M | 12.90M | 12.53M | 1.56M | 3.15M | 4.80M |
| Total Liabilities | 42.04M | 44.22M | 48.90M | 31.16M | 21.59M | 26.25M |
| Stockholders Equity | 43.63M | 44.67M | 34.33M | 20.22M | 20.68M | 22.30M |
Cash Flow | ||||||
| Free Cash Flow | -1.01M | 7.88M | 12.06M | 14.62M | -2.30M | 3.08M |
| Operating Cash Flow | 188.00K | 10.34M | 17.24M | 15.98M | -1.56M | 4.17M |
| Investing Cash Flow | -9.14M | -660.00K | -5.18M | -1.36M | -739.00K | 1.18M |
| Financing Cash Flow | -4.76M | -2.40M | -4.70M | -1.83M | -1.20M | 13.04M |
Open Orphan Plc Technical Analysis
Neutral
7.10
Price Trends
7.50
Negative
6.73
Positive
7.89
Negative
Market Momentum
-0.39
Positive
45.72
Neutral
47.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HVO, the sentiment is Neutral. The current price of 7.1 is below the 20-day moving average (MA) of 7.21, below the 50-day MA of 7.50, and below the 200-day MA of 7.89, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 47.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:HVO.
Open Orphan Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £48.53M | -137.50 | 11.97% | 2.94% | 11.92% | -33.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.00M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
44 Neutral | £17.82M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
42 Neutral | £298.31M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £8.58M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £17.56M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:HVO
Open Orphan Plc
7.05
-7.39
-51.16%
GB:AVCT
Avacta Group plc
68.20
32.20
89.44%
GB:IXI
IXICO plc
7.55
-0.20
-2.58%
GB:OBD
Oxford BioDynamics
0.20
-0.22
-52.38%
GB:FAB
Fusion Antibodies Plc
14.25
8.00
128.00%
GB:APTA
Aptamer Group Plc
0.60
0.34
130.77%
Open Orphan Plc Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
hVIVO Beats EBITDA Guidance as Acquisitions Cement Full-Service CRO Platform
Positive
Jan 29, 2026
hVIVO reported that 2025 revenue is expected to come in at about £46.7 million, in line with guidance but down from the prior year, while delivering a better-than-anticipated low single-digit positive adjusted EBITDA margin and maintaining a ...
Business Operations and StrategyFinancial Disclosures
hVIVO Sets Date for 2025 Trading Update and Investor Presentation
Positive
Jan 27, 2026
hVIVO plc has announced that it will release a trading update for the year ended 31 December 2025 on 29 January 2026, signalling upcoming visibility on its recent financial and operational performance. The company will host a live investor present...
Business Operations and StrategyExecutive/Board Changes
hVIVO Bolsters Board with Appointment of Richard Cotton as Non-Executive Director
Positive
Dec 18, 2025
hVIVO plc has appointed Richard Cotton as Independent Non-Executive Director, enhancing its board with his extensive financial and life sciences expertise. Cotton’s broad experience in financial leadership and governance within life sciences...
Business Operations and Strategy
hVIVO Leadership Increases Stake, Signaling Confidence in Growth
Positive
Dec 15, 2025
hVIVO plc announced that its CEO, Yamin ‘Mo’ Khan, and CFO, Stephen Pinkerton, have purchased additional shares in the company, reflecting their confidence in its future prospects. This move is likely to strengthen investor confidence ...
Business Operations and StrategyM&A Transactions
hVIVO’s Client Cidara Acquired by MSD After Successful Trial
Positive
Nov 27, 2025
hVIVO plc announced that its client, Cidara Therapeutics, has entered into an agreement to be acquired by Merck Sharp Dohme LLC for approximately $9.2 billion, following positive results from a Phase IIb trial of Cidara’s lead candidate, CD...
Business Operations and StrategyM&A Transactions
hVIVO’s Role in Cidara’s $9.2 Billion Acquisition by MSD
Positive
Nov 27, 2025
hVIVO plc announced that its client, Cidara Therapeutics, has been acquired by Merck Sharp Dohme LLC for approximately $9.2 billion following positive results from a Phase IIb trial of Cidara’s lead candidate, CD388. This acquisition highli...
Business Operations and Strategy
hVIVO’s German Subsidiary Secures £5 Million in New Contracts
Positive
Nov 20, 2025
hVIVO plc’s German subsidiary, CRS, has secured over £5 million in early-phase clinical trial service contracts with five clients, including two returning mid-sized German pharma companies. These contracts, which will commence in 2025 a...
Business Operations and StrategyProduct-Related Announcements
hVIVO Unveils Positive Data from Novel Human Challenge Models at Key Conferences
Positive
Nov 11, 2025
hVIVO plc has announced positive data from its novel human challenge models presented at key industry conferences in 2025. The company showcased its advancements in human challenge models for hMPV, SARS-CoV-2 Omicron, and RSV B, highlighting their...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.